Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$69.39 ▲ +3.19
(+4.82%)
MKT CAP: $16.40B • VOL: 5.07M
52W L $36 52W H $72
EXEL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-01-02 | FY 2024
FILED 2025-01-03 | FY 2023
FILED 2023-12-29 |
|---|---|---|---|
| Revenue (Total Sales) | $2.32B | $2.17B | $1.83B |
| YoY Revenue Growth % | +7.0% | +18.5% | — |
| Gross Profit | $2.24B | $2.09B | — |
| Gross Margin % | 96.4% | 96.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $872.2M | $604.6M | $170.9M |
| Operating Margin % | 37.6% | 27.9% | 9.3% |
| Net Income (GAAP) | $782.6M | $521.3M | $207.8M |
| EBITDA (Normalized) | $878.9M | $627.4M | $236.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $884.3M | $700.0M | $333.3M |
| Capital Expenditures (CapEx) | $8.4M | $28.4M | $82.4M |
| Free Cash Flow (FCF) | $875.8M | $671.5M | $251.0M |
| FCF Margin % | 37.7% | 31.0% | 13.7% |
| Return on Invested Capital (ROIC %) | 34.7% | 20.4% | 2.5% |
| Cash & Short-Term Equivalents | $482.5M | $217.4M | — |
| Total Debt (Short + Long Term) | $307.4M | $316.6M | $2.11B |
| Total Stockholders' Equity | $2.16B | $2.24B | $4.33B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EXEL.